About Castle Creek Pharma
Castle Creek Pharma is a company based in Basking Ridge (United States) founded in 2015. Castle Creek Pharma has raised $663.15 million across 3 funding rounds from investors including Fidelity Investments and Valor Equity Partners. The company has 72 employees as of December 31, 2021. Castle Creek Pharma has completed 1 acquisition, including Fibrocell Science. Castle Creek Pharma operates in a competitive market with competitors including Amryt Pharma, Castle Creek Biosciences, QID Pharma, Eicos Sciences and LifeMax, among others.
- Headquarter Basking Ridge, United States
- Employees 72 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$663.15 M (USD)
in 3 rounds
-
Latest Funding Round
$54.6 M (USD), Series C
Dec 09, 2019
-
Investors
Fidelity Investments
& 1 more
-
Employee Count
72
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Castle Creek Pharma
Castle Creek Pharma has successfully raised a total of $663.15M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $54.6 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Castle Creek Pharma
Castle Creek Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments and Valor Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
|
Locked | Locked | Locked |
Investor details for Castle Creek Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Castle Creek Pharma
Castle Creek Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fibrocell Science.
Investment portfolio details for Castle Creek Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints
|
Locked | Locked | 1995 | Locked |
Complete acquisition details for Castle Creek Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Castle Creek Pharma
Detailed financials for Castle Creek Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Castle Creek Pharma Comparisons
Peer comparison for Castle Creek Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Castle Creek Pharma
Castle Creek Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amryt Pharma, Castle Creek Biosciences, QID Pharma, Eicos Sciences and LifeMax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare dermatological and orphan diseases are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform for rare disease treatments is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic dermatology disorders are developed.
|
|
| Locked | Locked | Locked |
Develops Prostacyclin-based therapies for underserved medical conditions globally.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutic solutions for Netherton syndrome treatment.
|
Detailed competitors of Castle Creek Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Castle Creek Pharma
Complete news archive for Castle Creek Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Creek Pharma
Castle Creek Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Castle Creek Pharma is headquartered in Basking Ridge, United States. It is registered at Basking Ridge, New Jersey, United States.
Matthew Gantz is the current CEO of Castle Creek Pharma.
Castle Creek Pharma is a funded company, having raised a total of $663.15M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Castle Creek Pharma is 72.
Castle Creek Pharma, part of Paragon Biosciences, is developing drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders (UCDs). Its drug pipeline includes CCP-020 (diacerein 1 ointment) for the treatment of Epidermolysis Bullosa Simplex (Phase 3); CCP-040 which is in development for the treatment of oral and head and neck cancers (preclinical), as an adjuvant therapy to prevent recurrence; CCP-010, a molecular chaperone that is being developed as the first treatment option for patients with GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), a lysosomal storage disorder (Phase 23); CCP-110, in development for the treatment of hyperammonemia in UCDs (Phase 12) that acts by trapping ammonia ions in the gut and rapidly excreting them from the body.
Castle Creek Pharma's top competitors include Castle Creek Biosciences, Amryt Pharma and QID Pharma.
Castle Creek Pharma has made 1 acquisition, including Fibrocell Science.
Castle Creek Pharma has 2 investors. Key investors include Fidelity Investments, and Valor Equity Partners.